Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Humanized CAR19T2 T Cell in Children With Refractory/Relapsed B-cell Leukemia/Lymphoma

NCT05613348 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT05613348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05613348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Humanized CAR19T2 T Cell in Children With Refractory/Relapsed B-cell Leukemia/Lymphoma
Lead sponsor
Zhujiang Hospital
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 1, 2022
Completion date
December 1, 2028
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, b-cell lymphoma, unspecified